SCHEMBL762104

SCHEMBL762104

c1ccc2c(c1)NCC21CCNC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.47
HTR2A P28223 4/20 0.43
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
DRD2 P14416 1/20 0.43
HTR2C P28335 1/20 0.43
KDM1A O60341 1/20 0.41
OPRM1 P35372 3/20 0.39
OPRL1 P41146 1/20 0.39
TNKS O95271 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
AVPR1A P37288 1/20 0.35
CRBN Q96SW2 1/20 0.34
SIGMAR1 Q99720 1/20 0.33
KCNH2 Q12809 1/20 0.33
HDAC1 Q13547 1/20 0.33
CYP2D6 P10635 1/20 0.31
SLC6A3 Q01959 1/20 0.31
PDE7A Q13946 1/20 0.31
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11095419 1.00 BACE1 (0.47) BACE1HTR2ASLC6A2SLC6A4DRD2
SCHEMBL29387315 1.00 BACE1 (0.47) BACE1HTR2ASLC6A2SLC6A4DRD2
Hydrochloric Acid SCHEMBL25279576 0.98 BACE1 (0.46) BACE1HTR2ASLC6A2SLC6A4DRD2
SCHEMBL210677 0.91 BACE1 (0.45) BACE1HTR2ASLC6A2SLC6A4DRD2
SCHEMBL29384112 0.91 BACE1 (0.45) BACE1HTR2ASLC6A2SLC6A4DRD2
SCHEMBL30277974 0.89 HTR2A (0.46) BACE1HTR2ASLC6A2SLC6A4DRD2
Iodide SCHEMBL9047078 0.89 BACE1 (0.44) BACE1HTR2ASLC6A2SLC6A4DRD2
Hydrochloric Acid SCHEMBL6543309 0.89 BACE1 (0.44) BACE1HTR2ASLC6A2SLC6A4DRD2
Hydrochloric Acid SCHEMBL8063249 0.89 BACE1 (0.44) BACE1HTR2ASLC6A2SLC6A4DRD2
SCHEMBL1822909 0.84 OPRM1 (0.42) BACE1HTR2ASLC6A2SLC6A4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023164680-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS RECLUDIX PHARMA, INC. (US) 2023-08-31 WO claimed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 WO claimed
WO-2023164680-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS RECLUDIX PHARMA, INC. (US) 2023-08-31 WO disclosed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
CN-1047386-C Novel spiro [indole-pyrrolidine]derivatives as melatoninergic agonists, method for preparing same and use thereof as drug CEMAF (FR) 1999-12-15 CN disclosed
US-5763471-A TREATS PSYCHIATARIC AND BRAIN DISORDERS CEMAF (FR) 1998-06-09 US disclosed
CN-1148855-A Novel spiro [indole-pyrrolidine]derivatives as melatoninergic agonists, method for preparing same and use thereof as drug CEMAF (FR) 1997-04-30 CN disclosed
EP-0754183-A1 NOVEL SPIRO[INDOLE-PYRROLIDINE] DERIVATIVES AS MELATONINERGIC AGONISTS, METHOD FOR PREPARING SAME AND USE THEREOF AS A DRUG CEMAF (FR) 1997-01-22 EP disclosed
WO-1995027712-A1 NOVEL SPIRO[INDOLE-PYRROLIDINE] DERIVATIVES AS MELATONINERGIC AGONISTS, METHOD FOR PREPARING SAME AND USE THEREOF AS A DRUG CEMAF (FR) 1995-10-19 WO disclosed
US-4379932-A Process for preparing spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1983-04-12 US disclosed
US-4379933-A Process for preparing spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1983-04-12 US disclosed
US-4345081-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1982-08-17 US disclosed
US-4209625-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1980-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds HSD11B1, HSD3B1, HSD17B1 BACE1 557/4885HTR2A 2457/4885SLC6A2 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.